Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature.
A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8 microg) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.
Prieto-Lara
Elisa
E
Andalusian Agency for Health Technology Assessment, Emerging Technologies Observatory, Avd de la Innovación s/n, Edificio Renta Sevilla, Planta 2, 41020 Seville, Spain. prietoel@paho.org
Llanos-Méndez
Aurora
A
D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology / Q000592:standards*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D012449:Safety
D007252:Influenza Vaccines